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A b s t r A c t
Acute heart failure is a time critical disease and it is of outmost importance to identify 
the underlying precipitating factors as soon as possible as this can improve patient out-
comes. Infection is such a significant factor. Procalcitonin, as a biomarker of bacterial 
infection, can be used in acute heart failure patients to establish the diagnosis of con-
comitant bacterial infection. Procalcitonin can guide the early initiation of antibiotic 
therapy and provide prognostic information regarding acute heart failure patients. 
This short narrative review summarizes the current evidence on procalcitonin use 
in acute heart failure including the preliminary results of the IMPACT-BIC-18 trial.
I N t r O D U c t I O N
Acute heart failure (AHF) is defined as a rapid onset of new or worsening signs 
and symptoms of HF.1 It includes patients presenting for the first time with typical 
symptoms and signs of HF (de novo AHF) and also those with decompensation of 
their preexisting cardiomyopathy (acute decompensated HF). The European Society 
of Cardiology (ESC) guidelines recognize AHF as a time critical disease (like acute 
coronary syndromes) and stress the importance of identifying the underlying precipitat-
ing factors as soon as possible.2 This is actually the real challenge in AHF; to identify 
the underlying cause or precipitant that requires immediate attention and intervention. 
One of the most important and common precipitants is infection. It is thus essential 
to have a way to diagnose the concomitant presence of infection. Procalcitonin (PCT) 
is a 116 amino acid precursor of the hormone calcitonin, which is normally produced 
by the C-cells of the thyroid.3 During a bacterial infection PCT levels increase within 
2 to 4 hours of infection and peak around 24 to 48 hours and one can observe up to 
a 105-fold increase (C-reactive protein -CRP- in comparison shows only a 10- to 102-
fold increase).4 On the other hand, viral infections result in down-regulation of PCT. 
According to a recent Cochrane meta-analysis the use of PCT to guide initiation and 
duration of antibiotic treatment in acute respiratory tract infections results in lower 
risks of mortality, lower antibiotic consumption, and lower risk for antibiotic-related 
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side effects.5 Therefore, PCT is a marker of bacterial infection, 
and recent studies also propose its use in decision-making of 
antibiotic therapy in patients with AHF by identifying the 
patients with concomitant or triggering bacterial infection.4 
On the other hand, inflammation may be an important pre-
cipitating and/or causal factor in AHF, which may influence 
patient prognosis.4 The purpose of this short review is to pres-
ent the current knowledge on the use of PCT as a biomarker 
of inflammation and prognosis in AHF patients as well as a 
guiding biomarker for initiation of antibiotic therapy.
P c t  A s  A  b I O m A r K e r  O f 
I N f l A m m A t I O N  I N  A H f
Mesenteric venous congestion might cause inflammation 
in HF, by causing bacterial translocation from the intestinal 
lumen into the blood circulation, thus causing endotoxemia 
and immune activation.6 In this context, PCT levels are higher 
in patients with edematous HF as compared with patients with 
compensated HF and to controls without HF.7 PCT could 
be therefore an indicator of endotoxin-immune activation, 
as PCT levels correlate both with markers of inflammation 
and of venous congestion.8 In a Chinese study, that included 
4698 cases, it was shown that patients with simple HF had 
significantly higher PCT levels than normal controls, whereas 
patients with bacterial infection complicated by congestive 
HF had significantly higher PCT levels than those with simple 
infection.9 These findings further support a role of PCT as an 
inflammatory marker in AHF even in the absence of bacterial 
infection. Recently, a French group also concluded that AHF 
is associated with systemic inflammation and that PCT can be 
used as a biomarker to show this association.10
P c t  A s  A  P r O g N O s t I c  b I O m A r K e r  
I N  A H f
In a sub-study of the BACH trial, a significant associa-
tion was observed between high PCT levels (>0.21 ng/mL) 
and reduced survival rate of AHF patients assessed at 90 
days, compared to those with low PCT levels (<0.05 ng/
mL), but this trial also included patients with concomitant 
pneumonia.11 In the VERyfing DYspnea trial in the group 
of AHF patients the combined use of PCT plus mid-regional 
pro-atrial natriuretic peptide (MR-proANP) was able to 
predict both rehospitalization and death at 90 days.12 This 
was also shown in a smaller trial where baseline and serial in-
hospital measurements of PCT had a significant but modest 
prognostic value for 3-month all-cause mortality/hospitaliza-
tion in patients with AHF without clinical signs of infection 
at admission.13 In another trial of 261 AHF patients and no 
evidence of infection, PCT was independently and positively 
associated with the risk of long-term (median follow-up of 2 
years) death and recurrent hospitalizations.14 In 1781 patients 
of the PROTECT trial, which included AHF patients without 
clinical signs of infection, patients with AHF and significantly 
elevated PCT levels, indicating probable undiagnosed and/
or untreated bacterial infection, had poorer in-hospital and 
post-discharge outcomes, despite similar severity of HF.15 A 
recent meta-analysis of seven studies that measured PCT in 
HF patients, with or without infection showed that the mortal-
ity of HF patients whose serum PCT levels were elevated was 
significantly higher than that of HF patients whose PCT levels 
were normal at 30, 90, and 180 days.16 This meta-analysis adds 
further support on the prognostic information that PCT levels 
can have in AHF patients.
P c t  A s  A  b I O m A r K e r  t O  g U I D e 
A N t I b I O t I c  t r e A t m e N t  I N  A H f
The idea of using PCT as a biomarker to guide antibiotic 
therapy in AHF patients comes from studies that used PCT 
in patients with lower respiratory tract infections.5 Two stud-
ies exploring this concept were published in the last few years 
in the field of AHF. In the BACH trial, AHF patients with 
an elevated PCT concentration (>0.21 ng/mL) had a worse 
outcome if not treated with antibiotics, while patients with low 
PCT values (<0.05 ng/mL) had a better outcome if they did 
not receive any antibiotics.11 A sub-analysis from the ProHOSP 
trial, including only the 233 HF patients showed that conges-
tive HF patients presenting to the emergency department with 
respiratory symptoms and suspicion of respiratory infection 
had decreased antibiotic exposure and improved outcomes 
when PCT measurement was used to exclude bacterial infec-
tion and guide antibiotic treatment.17
N e w  e v I D e N c e
The results of the ACE 2 study regarding PCT were pub-
lished only a few months ago.18 PCT levels were measured 
<24 h of admission in 310 patients with acute dyspnea and 
compared to CRP and white blood cell (WBC) count in the 
total population and the subset of AHF patients. In AHF 
patients, PCT levels were superior to CRP and WBC in the 
diagnosis of concurrent pneumonia. Furthermore, during a 
median follow-up of 823 days PCT levels were associated with 
all-cause mortality. This association, however, did not remain 
statistically significant after multivariate analysis.18
The IMPACT-BIC-18 study (www.clinicaltrials.gov; 
NCT02392689) was a large, multicenter, randomized con-
trolled trial comparing PCT-guided patient management with 
standard management in the emergency department.4 The trial 
was initiated in 2014 and it was announced as a late-breaking 
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abstract presentation at the latest Heart Failure Association 
congress (May 2018, Vienna). Patients were enrolled if they 
presented to the emergency department with dyspnea and 
suspected AHF as indicated by increased levels of natriuretic 
peptides.4 A cut-off level of 0.2 ng/mL was used to decide 
the initiation of antibiotic therapy in the PCT-guided group, 
whereas antibiotic treatment was solely based on clinical judge-
ment in the control group. Patients were followed-up 30 and 
90 days after randomization to evaluate the survival status, 
hospitalizations, and antibiotic therapy variables.4 The study 
was prematurely terminated after randomizing 75% of the 
patients because there was no significant difference between 
the arms in either the primary endpoint of 90-day mortality 
or a secondary endpoint of 30-day mortality. As suggested by 
the leading investigator, the lack of benefit of a PCT-guided 
antibiotic initiation strategy might be due to two reasons; the 
relatively low risk of death (the total mortality rate was only 
9.2% compared with 18% reported on previous studies) and 
the very low infectious burden of the studied patient popula-
tion (the mean PCT level was 0.07 ng/mL and only 16.4% of 
patients had a level above 0.2 ng/mL).19
l I m I t A t I O N s
The purpose of this short manuscript was to present the 
latest evidence on the use of PCT in AHF and not to produce 
a systematic review on the topic. Given the narrative nature 
of this review, specific guidelines for conducting and reporting 
systematic reviews were not applied.
c O N c l U s I O N
PCT can potentially be a valuable tool for the cardiolo-
gist working at the emergency department and has also been 
included in the latest ESC guidelines as a lab test to be con-
sidered. In patients with AHF it can provide us with useful 
information regarding their management and prognosis. 
Furthermore, in countries, such as Greece, where there is 
increasing antibiotic oversubscription and antibiotic resistance, 
this is an extremely valuable addition to our armamentarium. 
We are advocating its use in the emergency department as 
a tool to help us in the decision to administer antibiotics to 
AHF patients in whom there is clinical uncertainty regarding 
a superimposed bacterial infection and to alarm us so that we 
can quickly involve an infectious disease expert in the manage-
ment of our patient.
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